The Grizzly, September 4, 2003

A Space to Call Your Own • Pay for Print Solution • Bumpy Ride • Spotlight on Politics: The California Recall • Feeling Disconnected: Internet and Virus Woes • A Plan for Every Future: Career Services Fall 2003 • Opinions: Campus Rooms: Is Space Running Out?; Network Gripes Getting you Down? Elections in California: Business as Usual or Free for All? • Activities, Activities, Activities • Calling all Thespians! • Ursinus in 1893: What was it Like? • New Arts Center • Local Heritage Day Celebration • Bears Versatility Makes the Season Look Promising • UC Field Hockey Team: Ready to Rumble • Promising Season Abound for the Men and Women\u27s Soccer Teams • Ursinus Cross Country Kicks-off • Ursinus Volleyball Team Off to Rough Start • X-Country Team Scoreshttps://digitalcommons.ursinus.edu/grizzlynews/1539/thumbnail.jp

The Grizzly, September 18, 2003

Senate Debates Future of Pell Grants • Presidential Address on Iraq • Downloading a Lawsuit • Working for the Weekend • How Accessible is Ursinus College? • Time of the Month not Every Month • Doors Close on an Urban Myth: Elevator Danger • Opinions: Zack\u27s: Not Always a Good Alternative; Have you Thanked Your Cleaning Staff Today?; The Negative Side of Reality TV; Out of the Middle East: Part Two • Nonsense! • An Off-campus Opportunity: Southlander • Potions, Pills and Prescriptions: Careers in the Pharmaceutical Industry • Dance with the Best! • Dave Matthews\u27 Experience: From the Eyes of UC Students • Student Profile: Jennifer Cackowski Challenged at Frankfurt Consulate • Price Comparison: Gas Prices • Bears Defense Crushes Catholic • Volleyball Team Continues Streaky Play • UC Cross Country Battles Elements and Competition • Women\u27s Soccer Team off to Best Start Ever • Men\u27s Soccer: Continuing to Fight • Field Hockey: Bears Lose Tough Onehttps://digitalcommons.ursinus.edu/grizzlynews/1541/thumbnail.jp

The Grizzly, September 11, 2003

Unique Organizations Attract New Members at Activities Fair • To Party or Not to Party: How is the Question • Reflections on the Post-September 11th World • An Anniversary Like No Other • A Major Decision • A Day in the Life: Lounge Living • Student Spotlight: Locks for Love • Activities Coming to You • Family Day at UC • John Mayer & Counting Crows • Opinions: Please Read: E-mail Abuse is Annoying; A Continuing Story: Out of the Middle East; The [De] Stabilized Situation in Iraq • 9/11: Reliving the Tragedy • SIGI Plus to the Rescue • UC on File Sharing: Joining the Bandwagon • Party Etiquette 101 • Price Comparison: Popular CDs • The Wit and Wisdom of J. D. Salinger • Bears Knock Out Susquehanna, 24-17 • Volleyball Team Makes it Three in a Row • TCNJ Field Hockey Blanks Ursinus • Men\u27s Soccer Comes out Even • Ursinus Women Dominate Soccer Classic • The Kobe Bryant Sagahttps://digitalcommons.ursinus.edu/grizzlynews/1540/thumbnail.jp

The Grizzly, November 6, 2003

Ursinus to Take its Place in the Future • Sticks and Stones: Hate Speech on Campus • Students Bug Out after Insect Invasion • Election Day: Mud Slinging and Politics • Look Back at October: Breast Cancer Month • Opinions: OCD: Harmless Passions or Medical Disorder?; Struggling with OCD, the Disorder; Finding Ways to Cope with the Parting of a Pet; Rush Limbaugh: Another Conservative Hypocrite; Pot Smoking Equals Lower Stamina?; Registering Online: An Extreme Inconvenience • Poet Comes to U.C. • Careers in Criminology and Investigation • Meet Dr. Kozusko: The New Shakespeare Professor • Perceptions of Greeks in the Media, UC • Greek Life Fifty Years Ago • Rushing: Is it for You? • Despite Loss, UC Football Team Remains Hopeful • UC XC Competes in Centennial Conference Championship • UC XC Holds 18th Annual Bear Pack Run 5K • Athletic Profile: Katie Dougherty • Women\u27s Rugby Team Makes History • UC Soccer Updateshttps://digitalcommons.ursinus.edu/grizzlynews/1547/thumbnail.jp

Salve Regina Arboretum Ten Year Plan to Reach Level III Accreditation

The Salve Regina University Arboretum, located in Newport, Rhode Island is currently registered as a Level II arboretum and is intertwined with the city of Newport Arboretum. The university now has intentions to reach Level III status, as part of a ten-year plan. This plan was developed by the students of the Spring 2018 BIO 255: Conservation Biology course, instructed by Dr. Jameson Chace, Associate Professor of biology at Salve Regina University. As part of a curriculum geared towards civic engagement, the class focused on creating and optimizing strategies that can be applied to the ten-year plan. These strategies were applied to the plan categorically: a team to inventory the current tree collection; a team to develop formal educational programming; a team for informal educational programming; a team to establish goals for conservation initiative related to the arboretum; a team dedicated to research related to arboreta; and a team to develop a list of species of special interest to add to the arboretum in the coming years. In the following document, each team’s strategies for the ten-year plan are outlined. Each of the components of this plan incorporate means to fulfill the conditions to meet Level III arboretum status so that the arboretum can apply for official registration. The aforementioned teams were tasked with designing a foundation on which to work up from. This includes formal educational programming to be applied to classroom settings and informal educational programming which can be applied to community outreach-based settings. The teams that worked to strengthen the arboretum’s mission of conservation focused on researching trees that can fit into the current landscape while providing some sort of benefit to the surrounding flora/fauna. Further, many of the species of interest, such as the chestnut, hold historical value to the greater Rhode Island region. In all, the Salve Regina Arboretum must achieve a total of 500 unique species of trees and woody plants as part of its efforts to apply for Level III status. In addition to the programming and research performed so far by the student teams, the arboretum must also hire a curator to manage the programming and to oversee the arboretum as a whole. Additionally, the arboretum must continue to actively collaborate with other arboreta and should encourage scientific research. It is important to recognize that the Salve Regina University Arboretum has already been utilized in the field of microbiology and has gained some attention at the university as a resource for further research and investigation. This ten year plan, along with resources within in it, is designed to provide a list of potential guidelines and ideas that can be applied for the arboretum’s benefit and growth. The Salve Regina University arboretum is a continually growing and developing part of the greater Newport, Rhode Island community, and will continue to strengthen its mission and that of the university which oversees its success.https://digitalcommons.salve.edu/bio255_arboretum/1000/thumbnail.jp

The phenotype of floating-harbor syndrome:clinical characterization of 52 individuals with mutations in exon 34 of SRCAP

Background\ud Floating-Harbor syndrome (FHS) is a rare condition characterized by short stature, delays in expressive language, and a distinctive facial appearance. Recently, heterozygous truncating mutations in SRCAP were determined to be disease-causing. With the availability of a DNA based confirmatory test, we set forth to define the clinical features of this syndrome.\ud \ud Methods and results\ud Clinical information on fifty-two individuals with SRCAP mutations was collected using standardized questionnaires. Twenty-four males and twenty-eight females were studied with ages ranging from 2 to 52 years. The facial phenotype and expressive language impairments were defining features within the group. Height measurements were typically between minus two and minus four standard deviations, with occipitofrontal circumferences usually within the average range. Thirty-three of the subjects (63%) had at least one major anomaly requiring medical intervention. We did not observe any specific phenotype-genotype correlations.\ud \ud Conclusions\ud This large cohort of individuals with molecularly confirmed FHS has allowed us to better delineate the clinical features of this rare but classic genetic syndrome, thereby facilitating the development of management protocols.The authors would like to thank the families for their cooperation and permission to publish these findings. SdM would like to thank Barto Otten. Funding was provided by the Government of Canada through Genome Canada, the Canadian Institutes of Health Research (CIHR) and the Ontario Genomics Institute (OGI-049), by Genome Québec and Genome British Columbia, and the Manton Center for Orphan Disease Research at Children’s Hospital Boston. KMB is supported by a Clinical Investigatorship Award from the CIHR Institute of Genetics. AD is supported by NIH grant K23HD073351. BBAdV and HGB were financially supported by the AnEUploidy project (LSHG-CT-2006-37627). This work was selected for study by the FORGE Canada Steering Committee, which consists of K. Boycott (University of Ottawa), J. Friedman (University of British Columbia), J. Michaud (University of Montreal), F. Bernier (University of Calgary), M. Brudno (University of Toronto), B. Fernandez (Memorial University), B. Knoppers (McGill University), M. Samuels (Université de Montréal), and S. Scherer (University of Toronto). We thank the Galliera Genetic Bank - “Telethon Genetic Biobank Network” supported by Italian Telethon grants (project no. GTB07001) for providing us with specimens

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570